First RET Inhibitor on Path to FDA Approval.
Investigators in the LIBRETTO-001 phase I/II trial presented new data on the experimental RET inhibitor selpercatinib at the 2019 World Conference on Lung Cancer. The agent produced robust responses in patients with RET-altered non-small cell lung cancer who had already received multiple therapies, raising hopes that it will soon receive FDA approval.